As per Attachment
AAREYDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aarey Drugs reported revenue from operations of Rs. 47,226.90 lakhs for FY26, marginally lower than the prior year's Rs. 47,394.33 lakhs — a decline of ~0.35%. Total income stood at Rs. 47,836.61 lakhs vs Rs. 48,375.57 lakhs in FY25. Profit before tax was Rs. 541.42 lakhs (vs Rs. 610.19 lakhs), and profit after tax was Rs. 396.76 lakhs (vs Rs. 402.39 lakhs), reflecting a ~1.4% YoY dip. Basic and diluted EPS remained flat at Rs. 1.39. The company raised Rs. 797.50 lakhs via preferential issue of convertible warrants in May 2025, with the balance consideration of Rs. 2,392.50 lakhs receivable upon exercise of warrants. The auditors issued an unmodified opinion with an Emphasis of Matter noting that debtors and creditors balances are subject to confirmation and relied upon management representation. No deviation in fund utilisation was reported.
Revenue and profit remained essentially flat year-on-year, suggesting business momentum was weak in FY26. The auditor's emphasis on unconfirmed receivables and payables raises some concern about balance sheet quality, though the unqualified opinion provides comfort on overall financial reporting integrity.